Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

BACKGROUND: The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. Resistant T315I clone may be present prior to initiating dasatinib, which could expand under selective pressures during treatment. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoto, Miura, Masatomo, Scott, Stuart A, Niioka, Takenori, Sawada, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409074/
https://www.ncbi.nlm.nih.gov/pubmed/22587422
http://dx.doi.org/10.1186/1756-8722-5-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409074/
https://www.ncbi.nlm.nih.gov/pubmed/22587422
http://dx.doi.org/10.1186/1756-8722-5-23

Ejemplares similares